The US FDA requires holders of applications for GLP-1 receptor agonist medications to add a warning about a potential increased risk of NAION, a rare but serious eye condition.
1. Labeling changes required
The US FDA said application holders for GLP-1 receptor agonist medications must add information about the potential increased risk of NAION to the warnings and precautions section of their safety labeling.
XLV•
